NO20031642D0 - Humaniserte anti-LT-O-R-antistoff - Google Patents

Humaniserte anti-LT-O-R-antistoff

Info

Publication number
NO20031642D0
NO20031642D0 NO20031642A NO20031642A NO20031642D0 NO 20031642 D0 NO20031642 D0 NO 20031642D0 NO 20031642 A NO20031642 A NO 20031642A NO 20031642 A NO20031642 A NO 20031642A NO 20031642 D0 NO20031642 D0 NO 20031642D0
Authority
NO
Norway
Prior art keywords
antibody
humanized anti
humanized
Prior art date
Application number
NO20031642A
Other languages
English (en)
Other versions
NO20031642L (no
Inventor
Ellen A Garber
Paul Lyne
Jose William Saldanha
Original Assignee
Biogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Inc filed Critical Biogen Inc
Publication of NO20031642D0 publication Critical patent/NO20031642D0/no
Publication of NO20031642L publication Critical patent/NO20031642L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
NO20031642A 2000-10-13 2003-04-10 Humaniserte anti-LT-ß-R-antistoff NO20031642L (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US24028500P 2000-10-13 2000-10-13
US27528901P 2001-03-13 2001-03-13
US29998701P 2001-06-21 2001-06-21
PCT/US2001/032140 WO2002030986A2 (en) 2000-10-13 2001-10-12 HUMANIZED ANTI-LT-β-R ANTIBODIES

Publications (2)

Publication Number Publication Date
NO20031642D0 true NO20031642D0 (no) 2003-04-10
NO20031642L NO20031642L (no) 2003-06-13

Family

ID=27399340

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20031642A NO20031642L (no) 2000-10-13 2003-04-10 Humaniserte anti-LT-ß-R-antistoff

Country Status (25)

Country Link
US (2) US7429644B2 (no)
EP (1) EP1326897A2 (no)
JP (1) JP2004532608A (no)
KR (1) KR20030041164A (no)
CN (1) CN1547590A (no)
AR (1) AR035352A1 (no)
AU (2) AU2002211747B2 (no)
BG (1) BG107802A (no)
BR (1) BR0114646A (no)
CA (1) CA2425809A1 (no)
CZ (1) CZ20031307A3 (no)
EA (1) EA006945B1 (no)
EE (1) EE200300179A (no)
GE (1) GEP20063752B (no)
HU (1) HUP0302573A2 (no)
IL (1) IL155340A0 (no)
IS (1) IS6779A (no)
MX (1) MXPA03003144A (no)
NO (1) NO20031642L (no)
NZ (1) NZ525793A (no)
PL (1) PL366307A1 (no)
SK (1) SK5672003A3 (no)
TR (2) TR200602095T2 (no)
WO (1) WO2002030986A2 (no)
YU (1) YU28503A (no)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6312691B1 (en) * 1996-01-26 2001-11-06 Jeffrey L. Browning Lymphotoxin-α/β complexes and anti-lympotoxin-β receptor antibodies as anti-tumor agents
US5925351A (en) 1995-07-21 1999-07-20 Biogen, Inc. Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease
JP2005532051A (ja) * 2002-07-01 2005-10-27 バイオジェン， インコーポレイテッド ヒト化抗リンホトキシンβレセプター抗体
AU2003299984A1 (en) * 2002-12-20 2004-07-22 Biogen Idec Ma Inc. Multivalent lymphotoxin beta receptor agonists and therapeutic uses thereof
PL377611A1 (pl) * 2002-12-20 2006-02-06 Biogen Idec Ma Inc. Czynniki dla receptora limfotoksyny beta w połączeniu z czynnikami chemioterapeutycznymi
US7700097B2 (en) 2003-06-27 2010-04-20 Biogen Idec Ma Inc. Purification and preferential synthesis of binding molecules
CA2545603A1 (en) 2003-11-12 2005-05-26 Biogen Idec Ma Inc. Neonatal fc receptor (fcrn)-binding polypeptide variants, dimeric fc binding proteins and methods related thereto
CN1980957A (zh) 2004-03-23 2007-06-13 比奥根艾迪克Ma公司 受体偶联剂及其治疗用途
US8153123B2 (en) * 2004-12-09 2012-04-10 La Jolla Institute For Allergy And Immunology Method for restoring dendritic cell populations
WO2006074399A2 (en) 2005-01-05 2006-07-13 Biogen Idec Ma Inc. Multispecific binding molecules comprising connecting peptides
PL2500030T5 (pl) 2005-11-04 2019-02-28 Genentech, Inc. Zastosowanie inhibitorów drogi aktywacji dopełniacza w leczeniu chorób oczu
JP2007295524A (ja) * 2006-03-28 2007-11-08 Denso Corp 情報通信システム、施設側装置、ユーザ側装置、管理装置、車両側装置、施設側プログラム、ユーザ側プログラム、管理プログラム及び車両側プログラム
WO2007137984A2 (en) * 2006-05-25 2007-12-06 Glaxo Group Limited Modified humanised anti-interleukin-18 antibodies
EP2067041A2 (en) 2006-10-03 2009-06-10 Biogen Idec MA, Inc. Biomarkers and assays for the treatment of cancer
MX2009003774A (es) 2006-10-12 2009-04-22 Genentech Inc Anticuerpos para linfotoxina-alfa.
EP2311481A3 (en) * 2006-10-20 2013-10-16 Biogen Idec MA Inc. Treatment of demyelinating disorders with soluble lymphotoxin-beta-receptor
US8338376B2 (en) * 2006-10-20 2012-12-25 Biogen Idec Ma Inc. Compositions comprising variant LT-B-R-IG fusion proteins
CN106084055A (zh) 2006-11-02 2016-11-09 健泰科生物技术公司 人源化的抗‑d因子抗体
US8003761B2 (en) * 2007-01-23 2011-08-23 Hoffmann-La Roche Inc. Cancerous disease modifying antibodies
CL2008001071A1 (es) * 2007-04-17 2009-05-22 Smithkline Beecham Corp Metodo para obtener anticuerpo penta-especifico contra il-8/cxcl8, gro-alfa/cxcl1, gro-beta/cxcl2), gro-gama/cxcl3 y ena-78/cxcl5 humanas; anticuerpo penta-especifico; proceso de produccion del mismo; vector, hbridoma o celela que lo comprende; composicion farmceutica; uso para tratar copd, otras enfermedades.
NZ581468A (en) 2007-06-25 2012-09-28 Esbatech Alcon Biomed Res Unit Methods of modifying antibodies, and modified antibodies with improved functional properties
CR20170001A (es) 2008-04-28 2017-08-10 Genentech Inc Anticuerpos anti factor d humanizados
TWI513465B (zh) 2009-06-25 2015-12-21 Regeneron Pharma 以ｄｌｌ４拮抗劑與化學治療劑治療癌症之方法
CN103842383B (zh) 2011-05-16 2017-11-03 健能隆医药技术（上海）有限公司 多特异性fab融合蛋白及其使用方法
US9738707B2 (en) 2011-07-15 2017-08-22 Biogen Ma Inc. Heterodimeric Fc regions, binding molecules comprising same, and methods relating thereto
US10093978B2 (en) 2013-08-12 2018-10-09 Genentech, Inc. Compositions for detecting complement factor H (CFH) and complement factor I (CFI) polymorphisms
BR112016025312A2 (pt) 2014-05-01 2017-10-17 Genentech Inc variantes de anticorpo, anticorpo anti-fator d, formulação farmacêutica, dispositivo de distribuição, utilização da formulação e de uma composição, composição e método de tratamento de uma desordem
CA2960797A1 (en) 2014-11-06 2016-05-12 F. Hoffmann-La Roche Ag Fc-region variants with modified fcrn-binding and methods of use
IL256800B2 (en) 2015-07-14 2023-04-01 Immunext Inc An anti-cd154 antibody with improved binding, functional and safety properties and use in human immunotherapy
EP3368074A2 (en) 2015-10-30 2018-09-05 Hoffmann-La Roche AG Anti-factor d antibodies and conjugates
EP3368090A1 (en) 2015-10-30 2018-09-05 H. Hoffnabb-La Roche Ag Anti-factor d antibody variant conjugates and uses thereof
EP3430058A4 (en) 2016-03-15 2019-10-23 Generon (Shanghai) Corporation Ltd. MULTISPECIFIC FAB FUSION PROTEINS AND USES THEREOF
JP2023506750A (ja) 2019-12-11 2023-02-20 シラグ・ゲーエムベーハー・インターナショナル Ｌｔｂｒ及びｅｄｂ結合ドメインを含む多重特異性結合分子並びにその使用
WO2022117572A2 (en) 2020-12-02 2022-06-09 Oncurious Nv An ltbr agonist in combination therapy against cancer
WO2022117569A1 (en) 2020-12-02 2022-06-09 Oncurious Nv A ccr8 antagonist antibody in combination with a lymphotoxin beta receptor agonist antibody in therapy against cancer
AR128031A1 (es) 2021-12-20 2024-03-20 Hoffmann La Roche Anticuerpos agonistas anti-ltbr y anticuerpos biespecíficos que los comprenden
WO2023198848A1 (en) 2022-04-13 2023-10-19 Vib Vzw An ltbr agonist in combination therapy against cancer
WO2023218320A1 (en) * 2022-05-11 2023-11-16 Pfizer Inc. Anti-lymphotoxin beta receptor antibodies and methods of use thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5618920A (en) * 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
CA2086264C (en) 1990-06-27 2002-12-24 Jeffrey L. Browning Surface complexed lymphotoxin
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
WO1994004679A1 (en) * 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
CA2150249A1 (en) 1992-12-04 1994-06-23 Jeffrey Browning Lymphotoxin-.beta., lymphotoxin-.beta. complexes, pharmaceutical preparations and therapeutic uses thereof
US6312691B1 (en) * 1996-01-26 2001-11-06 Jeffrey L. Browning Lymphotoxin-α/β complexes and anti-lympotoxin-β receptor antibodies as anti-tumor agents
CN1589902A (zh) * 1995-01-26 2005-03-09 拜奥根有限公司 抗－LT－β－R抗体在制备药用组合物中的应用
US5925351A (en) * 1995-07-21 1999-07-20 Biogen, Inc. Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease
US7060667B1 (en) * 1998-01-30 2006-06-13 Biogen Idec Ma, Inc. Treatment of follicular lymphomas using inhibitors of the LT pathway
CN1287853C (zh) 1998-01-30 2006-12-06 拜奥根Idec马萨诸塞公司 用淋巴毒素(lt)途径抑制物治疗滤泡性淋巴瘤
GB9809839D0 (en) 1998-05-09 1998-07-08 Glaxo Group Ltd Antibody
JP2005532051A (ja) * 2002-07-01 2005-10-27 バイオジェン， インコーポレイテッド ヒト化抗リンホトキシンβレセプター抗体
AU2003299984A1 (en) * 2002-12-20 2004-07-22 Biogen Idec Ma Inc. Multivalent lymphotoxin beta receptor agonists and therapeutic uses thereof
PL377611A1 (pl) * 2002-12-20 2006-02-06 Biogen Idec Ma Inc. Czynniki dla receptora limfotoksyny beta w połączeniu z czynnikami chemioterapeutycznymi

Also Published As

Publication number Publication date
MXPA03003144A (es) 2004-12-06
IL155340A0 (en) 2003-11-23
KR20030041164A (ko) 2003-05-23
GEP20063752B (en) 2006-02-27
EP1326897A2 (en) 2003-07-16
TR200300478T2 (tr) 2004-10-21
EA006945B1 (ru) 2006-06-30
BR0114646A (pt) 2006-02-21
NO20031642L (no) 2003-06-13
AU2002211747B2 (en) 2007-11-29
AU1174702A (en) 2002-04-22
NZ525793A (en) 2008-04-30
US7429644B2 (en) 2008-09-30
SK5672003A3 (en) 2003-10-07
PL366307A1 (en) 2005-01-24
WO2002030986A2 (en) 2002-04-18
CN1547590A (zh) 2004-11-17
TR200602095T2 (tr) 2007-02-21
CA2425809A1 (en) 2002-04-18
CZ20031307A3 (cs) 2003-10-15
US20040058394A1 (en) 2004-03-25
AR035352A1 (es) 2004-05-12
WO2002030986A3 (en) 2003-03-13
US20090092601A1 (en) 2009-04-09
YU28503A (sh) 2006-05-25
HUP0302573A2 (hu) 2003-10-28
IS6779A (is) 2003-04-11
JP2004532608A (ja) 2004-10-28
BG107802A (bg) 2004-01-30
EA200300464A1 (ru) 2003-10-30
EE200300179A (et) 2003-08-15

Similar Documents

Publication Publication Date Title
NO20031642L (no) Humaniserte anti-LT-ß-R-antistoff
DE60222658D1 (de) Monoklonaler anti-cd-40-antikörper
IL156030A0 (en) Humanized antibodies
IS6982A (is) Mótefni gegn VLA-1
NO20044347L (no) Anti-alfavbeta6-antistoff
DK1501856T3 (da) Anti-HER2 antistofvarianter
DE50100900D1 (de) Fixierelement
DK1314437T3 (da) Stabiliserede antistofindeholdende præparater
DE60044829D1 (de) Chromenverbindung
DK1226127T3 (da) Substituerede phenylsulfamoylcarboxamider
DE60114153D1 (de) Substituierte arylpyrazine
AR028393A1 (es) Iminoazidas substituidas
DE10085449T1 (de) Fixiervorrichtung
NO20032338L (no) Tappekran
EE200300569A (et) CD44v6-spetsiifilised antikehad
DK1164375T3 (da) Assay til antitransglutaminaseantistoffer
AR028302A1 (es) Feniluracilos substituidos
DE50112662D1 (de) Substituierte benzoylcyclohexenone
DE60104562D1 (de) Bewegungsmechanismus
FI20011055A0 (fi) Heveiiniä sitovat monoklonaaliset vasta-aineet
ITPD20000192A0 (it) Anticorpi policlonali
DE60135621D1 (de) Fixiergerät
AR028262A1 (es) Anticuerpos especificos de fap-alfa humanos
DK1503799T3 (da) Immunogent, monoklonalt antistof
GB0029846D0 (en) Monoclonal antibody

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application